RetroSense Therapeutics Secures Exclusive Worldwide Rights to ReaChR Optogene from the University of California San Diego

ANN ARBOR, Mich.--(BUSINESS WIRE)--RetroSense Therapeutics LLC, a privately-held, clinical-stage biopharmaceutical company, today announced the Company has signed a worldwide license with the University of California San Diego to secure exclusive rights to develop red activatable channelrhodopsin (ReaChR), a next-generation optogene developed by the late Nobel Laureate Roger Y. Tsien, Ph.D. Financial terms were not disclosed. “The ReaChR license allows us to continue building on our world-leadi